2020 年, 国家药品监督管理局颁布了《 模型引导的药物研发技术指导原则》 等技术指南,
为建模与模拟技术在新药研发中的应用提供了技术指导. 2022 年7 月, 为了解国内新药研发企业 …

Guideline of model-informed drug development was published by National Medical
Products Administration in 2020, which provided technical guidance for the application of …

Model-informed drug development (MIDD) is the application of a wide range of
mathematical, statistical, and biological models to facilitate drug development, decision …

Model-informed drug development (MIDD) refers to the application of various mathematical
models in drug development, in order to facilitate the decision-making process. There have …

Drug development is fraught with difficulties, and pharmaceutical technology is becoming
increasingly complex. With the development of computer technology, the pharmaceutical …

抄録 Over the last two decades, we have impacted decision making on numerous
frontsthrough the application of model-informed drug discovery and development (MIDD) …

Model-informed drug development (MIDD) utilizes the knowledge extracted from relevant
data to improve the efficiency of decision making within the pharmaceutical industry. The …

Abstract Model-informed drug development (MIDD) is a powerful approach to support drug
development and regulatory review. There is a rich history of MIDD applications at the US …

Global alignment of expectations is required to achieve consistency in the planning,
conduct, reporting, and regulatory review of modelinformed drug development (MIDD) …

Model-informed drug development (MIDD) is a powerful approach to increase efficiency in
drug development, impact regulatory outcomes, and improve drug benefit–risk balance. 1, 2 …